Literature DB >> 11680585

Comparative study analyzing effects of sirolimus-cyclosporin and sirolimus-tacrolimus combinations on bile flow in the rat.

M Deters1, K Nolte, G Kirchner, K Resch, V Kaever.   

Abstract

The new immunosuppressive agent sirolimus is combined in transplant patients with the cholestatic substances cyclosporin and tacrolimus. Nothing is known about possible cholestatic effects of these combinations. Therefore, we compared their effects on bile flow and on important bile parameters in an acute bile fistula model in rats. Cyclosporin reduced bile flow, biliary excretion of bile salts, cholesterol, and GSH to 20-40% of basal values. Sirolimus decreased bile flow to 50% and excretion of GSH to 30% of the initial conditions but had no effect on cholesterol and bile salt excretion. In contrast, tacrolimus increased bile flow to 120% and GSH excretion to 220% of the basal levels. Sirolimus/cyclosporin decreased bile flow and bile parameters to the same extent as cyclosporin alone. Sirolimus/tacrolimus reversed sirolimus-induced reduction of bile flow and GSH excretion and resulted in a normal bile salt and cholesterol excretion, thus it may be the better alternative in cholestatic patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680585     DOI: 10.1023/a:1011942310737

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Enzymatic assay for glutathione.

Authors:  J E Brehe; H B Burch
Journal:  Anal Biochem       Date:  1976-07       Impact factor: 3.365

Review 2.  Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy.

Authors:  W M Bennett; A DeMattos; M M Meyer; T Andoh; J M Barry
Journal:  Kidney Int       Date:  1996-10       Impact factor: 10.612

3.  The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.

Authors:  M G Murgia; S Jordan; B D Kahan
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

4.  Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

Authors:  B D Kahan; B A Julian; M D Pescovitz; Y Vanrenterghem; J Neylan
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

5.  Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.

Authors:  C C Paulusma; M A van Geer; R Evers; M Heijn; R Ottenhoff; P Borst; R P Oude Elferink
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

6.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

Authors:  M Sattler; F P Guengerich; C H Yun; U Christians; K F Sewing
Journal:  Drug Metab Dispos       Date:  1992 Sep-Oct       Impact factor: 3.922

Review 7.  Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.

Authors:  S N Sehgal
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

8.  Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver.

Authors:  M Böhme; M Müller; I Leier; G Jedlitschky; D Keppler
Journal:  Gastroenterology       Date:  1994-07       Impact factor: 22.682

9.  Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy.

Authors:  D K Granger; J W Cromwell; S C Chen; J J Goswitz; D T Morrow; F A Beierle; S N Sehgal; D M Canafax; A J Matas
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

10.  Cyclosporine A hepatotoxicity: effect of prolonged treatment with cyclosporine on biliary lipid secretion in the rat.

Authors:  A I Galán; E Fernández; D Morán; M E Muñoz; R Jiménez
Journal:  Clin Exp Pharmacol Physiol       Date:  1995-04       Impact factor: 2.557

View more
  3 in total

1.  Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model.

Authors:  Michael Deters; Til Klabunde; Gabriele Kirchner; Klaus Resch; Volkhard Kaever
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

2.  Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats.

Authors:  Michael Deters; Gabriele Kirchner; Therese Koal; Klaus Resch; Volkhard Kaever
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

3.  Biliary diseases in heart transplanted patients: a comparison between cyclosporine A versus tacrolimus-based immunosuppression.

Authors:  J Stief; H U Stempfle; M Götzberger; P Uberfuhr; M Köpple; P Lehnert; C Kaiser; Uwe Schiemann
Journal:  Eur J Med Res       Date:  2009-05-14       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.